Centene Stock Earnings Reports

Centene reported a strong start to 2026 with Q1 adjusted diluted EPS of $3.37, beating prior expectations and enabling the company to raise full-year adjusted EPS guidance to >$3.40 (up from >$3.00). Key drivers: Medicaid and Medicare outperformed expectations (Medicaid HBR improvement and Medicare Advantage/PDP favorability), while Marketplace results were broadly in line with expectations though Q1 Silver-tier utilization was higher-than-expected and Centene has taken a conservative posture for the remainder of the year pending June Wakely data. Management highlighted continued progress on Medicaid margin restoration through standardized trend-management initiatives (utilization management, clinical programs, network optimization, payment integrity and anti–fraud efforts), constructive rate discussions with states (Medicaid composite rate yield ~4.5%), and momentum in Medicare (MA membership aligned with Medicaid footprint, PDP ~8.7M members, improved MA/PDP HBRs and a path toward MA breakeven in 2027). Balance sheet and cash: strong operating cash flow ($4.4B Q1), $437M available for general corporate use, reduced debt-to-capital to 43.2% after a $1B receivable sale used to repurchase notes. SG&A discipline continued (consolidated SG&A ratio 7.6%). Management emphasized prudence on Marketplace risk-adjustment recognition (embedding only a partial RA offset in current guidance) and expects Q2–Q4 seasonality (EPS step down in Q2, ~breakeven in Q3, seasonally loss in Q4). They also noted expansion of analytics and selective AI tools for forecasting and payment integrity, and ongoing engagement with CMS on program integrity reforms and Medicare initiatives (Bridge program, GLP-1 access).